George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss ongoing research to watch in acute lymphoblastic leukemia.

Ongoing Research to Watch in Acute Lymphoblastic Leukemia

Videos

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss how to incorporate blinatumomab into clinical practice for ALL.

Incorporating Blinatumomab into Clinical Practice for ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss adverse effect management in acute lymphoblastic leukemia.

Mitigation and Management Strategies for ICANS and Other AEs in ALL 

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss data for blinatumomab plus chemotherapy in newly diagnosed pediatric ALL.

Approaching First-Line Treatment Decisions in Pediatric ALL

Blinatumomab Plus Chemo in Newly Diagnosed, Standard-Risk Pediatric B-ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, discuss first-line treatment considerations for pediatric ALL.

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on blinatumomab as consolidation therapy in older patients with newly diagnosed ALL.

Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–negative B-ALL

Adding Blinatumomab to Consolidation Therapy in Older Patients With Newly Diagnosed, BCR::ABL1–Negative B-ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on alloHCT outcomes from the ECOG ACRIN E1910 trial of blinatumomab. 

AlloHCT Outcomes From ECOG ACRIN E1910 in Newly Diagnosed, MRD-Negative B-Lineage ALL

George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.

Frontline Treatment Considerations in Adult and Pediatric Acute Lymphoblastic Leukemia

6365822149112

Rachel E. Rau, MD, pediatric oncologist, Seattle Children’s Hospital, University of Washington, discusses results from the phase 3 Children’s Oncology Group Study AALL1731 (NCT03914625), which showed that adding 

blinatumomab (Blincyto) to chemotherapy improved 3-year disease-free survival rates

 in newly diagnosed, standard risk pediatric B-cell acute lymphoblastic leukemia.  Rau and colleagues shared these results in a presentation at the 

 Rachel E. Rau, MD, discusses findings that show blinatumomab plus chemotherapy improves DFS in newly diagnosed B-ALL.

Rachel Elizabeth Rau, MD

Articles